Biomedical Engineering Reference
In-Depth Information
247. Bjork, I. et al., Permanent activation of antithrombin by covalent attachment of heparin oligosaccha-
rides,
FEBS Lett
., 143, 96, 1982.
248. Halluin, A.P., Protein heparin conjugates, U.S. Patent No. 5,308,617, 1994.
249. Dawes, J., James, K., and Lane, D.A., Conformational change in antithrombin induced by heparin
probed with a monoclonal antibody against the heparin 1C/4B region,
Biochemistry
, 33, 4375, 1994.
250. Mitra, G. and Jordan, R.E., Covalently bound heparin-antithrombin III complex, U.S. Patent No.
4,689,323, 1987.
251. Mitra, G. and Jordan, R.E., Covalently bound heparin-antithrombin III complex, method for its prepara-
tion and its use for treating thromboembolism, European Patent No. 0-137-356, 1985.
252. Vlassara, H., Brownlee, M., and Cerami, A., Nonenzymatic glycosylation: Role in the pathogenesis of
diabetic complications,
Clin. Chem
., 32, B37, 1986.
253. Hall, P. et al., Functional activities and non-enzymatic glycosylation of plasma proteinase inhibitors in
diabetes,
Clin. Chim. Acta
, 160, 55, 1986.
254. Ceriello, A. et al., Daily rapid blood glucose variations may condition antithrombin III biologic activity
but not its plasma concentration in insulin-dependent diabetes. A possible role for labile non-enzymatic
glycation,
Diabete. Metab
., 13, 16, 1987.
255. Ceriello, A. et al., Decreased antithrombin III activity in diabetes may be due to non-enzymatic glyco-
sylation—a preliminary report,
Thromb. Haemost
., 50, 633, 1983.
256. Villanueva, G.B. and Allen, N., Demonstration of altered antithrombin III activity due to non-enzymatic
glycosylation at glucose concentration expected to be encountered in severely diabetic patients,
Diabe-
tes
, 37, 1103, 1988.
257. Brownlee, M., Vlassara, H., and Cerami, A., Inhibition of heparin-catalyzed human antithrombin III
activity by non-enzymatic glycosylation. Possible role in fi brin deposition in diabetes,
Diabetes
, 33, 532,
1984.
258. Sakurai, T., Boissel, J.P., and Bunn, H.F., Non-enzymatic glycation of antithrombin III
in vitro
,
Biochim. Biophys. Acta
, 964, 340, 1988.
259. Brownlee, M. and Cerami, A., A glucose-controlled delivery system: Semi-synthetic insulin bound to
lectin,
Science
, 206, 1190, 1979.
260. Hoffman, J., Larm, O., and Scholander, E., A new method for covalent coupling of heparin and other
glycosaminoglycans to substances containing primary amino groups,
Carb. Res
., 117, 328, 1983.
261. Berry, L., Chan, A.K.C., and Andrew, M., Polypeptide-polysaccharide conjugates produced by sponta-
neous non-enzymatic glycation,
Biochem.
J
., 124, 434, 1998.
262. Busby, T.F. and Ingham, K.C., Thermal stabilization of antithrombin III by sugars and sugar derivatives
and the effects of non-enzymatic glycosylation,
Biochim. Biophys. Acta
, 799, 80, 1984.
263. Mewhort-Buist, T.A. et al., Structural effects of a covalent linkage between antithrombin and heparin:
Covalent N-terminus attachment of heparin enhances the maintenance of antithrombin's activated state,
Biochem.
J
., 140, 175, 2006.
264. Berry, L. et al., Investigation of the anticoagulant mechanisms of a covalent antithrombin-heparin com-
plex,
J. Biol. Chem
., 273, 34730, 1998.
265. Chan, A.K.C. et al., Isoform composition of antithrombin in a covalent antithrombin-heparin complex,
Biochem. Biophys. Res. Comm
., 309, 986, 2003.
266. Patel, S., Berry, L.R., and Chan, A.K.C., Analysis of inhibition rate enhancement by covalent
linkage of heparin to antithrombin as a potential predictor of reaction mechanism,
Biochem.
J
.,
141, 25, 2007.
267. Jordan, R.E. et al., Heparin with two binding sites for antithrombin or platelet factor 4,
J. Biol. Chem
.,
257, 400, 1982.
268. Chan, A.K.C. et al., Decreased concentrations of heparinoids are required to inhibit thrombin genera-
tion in plasma from newborns and children compared to plasma from adults due to reduced thrombin
potential,
Thromb. Haemost
., 87, 606, 2002.
269. Parmar, N. et al., Effect of heparins on thrombin generation in hemphilic plasma supplemented with
FVIII, FVIIa, or FEIBA,
Clin. Lab
., 51, 157, 2005.
270. Hoylaerts, M. et al., Covalent complexes between low molecular weight heparin fragments and anti-
thrombin III—inhibition kinetics and turnover parameters,
Thromb. Haemost
., 49, 109, 1983.
271. Collen, D.J., Novel composition of matter of antithrombin III bound to a heparin fragment, U.S. Patent
No. 4,623,718, 1986.
272. Mattsson, C. et al., Antithrombotic properties in rabbits of heparin and heparin fragments covalently
coupled to human antithrombin III,
J. Clin. Invest
., 75, 1169, 1985.
